A new target for diabetes therapy: Advances in the research of glycogen synthase kinase-3 inhibitors

Yaoxue Xuebao

Volumn 42, Issue 12, 2007, Pages 1227-1231

  Liu, Shuai nan ^a   Shen, Zhu fang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Diabetes; Glycogen synthase; Glycogen synthase kinase 3; Insulin resistance; Insulin signaling pathway

Indexed keywords

ENZYME INHIBITOR; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; INSULIN;

ALZHEIMER DISEASE; ANIMAL; DIABETES MELLITUS; DRUG ANTAGONISM; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; ENZYME INHIBITORS; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN; INSULIN RESISTANCE; SIGNAL TRANSDUCTION;

EID: 38949124424     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Cohen P, Yellowlees D, Aitken A, et al. Separation and characterisation of glycogen synthase kinase 3, glycogen synthase kinase 4, glycogen synthase kinase 5 from rabbit skeletal muscle [J]. Eur J Biochem, 1982,124:21-35.
2. Cohen P, Nimmo HG, Proud CG. How does insulin stimulate glycogen synthesis [J]. Biochem Soc Symp, 1978,43:69-95.
3. Kockeritz L, Doble B, Patel S, et al. Glycogen synthase kinase-3, an overview of an over-achieving protein kinase [J]. Curr Drug Targets, 2006,7:1377-1388.
4. Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3 [J]. Methods Enzymol, 1991,200: 564-577.
5. Noble ME, Endicott JA, Johnson LN, et al. Protein kinase inhibitors: insights into drug design from structure [J]. Science, 2004,303:1800-1805.
6. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery [J]. Biochem J, 2001,359: 1-16.
7. Dokken BB, Sloniger JA, Henriksen EJ. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle [J]. Am J Physiol Endocrinol Metab, 2005,288: 1188-1194.
8. Pearce NJ, Arch JC, Clapham MP, et al. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3 on a muscle-specific promoter [J]. Metabolism, 2004, 53: 1322-1330.
9. Lochhead PA, Coghlan M, Rice SQ, et al. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression [J]. Diabetes, 2001,50:937-946.
10. Kim YB, Peroni OD, Aschenbach WG, et al. Muscle-specific deletion of the Glut4 glucose transporter alters multiple regulatory steps in glycogen metabolism [J]. Mol Cell Biol, 2005,11:9713-9723.
11. Henriksen EJ, Dokken BB. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes [J]. Curr Drug Targets, 2006,7:1435-1441.
12. Dokken BB, Henriksen EJ. Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in pre-diabetic obese Zucker rats [J]. Am J Physiol Endocrinol Metab, 2006,291: 209-213.
13. Rao R, Zhang MZ, Zhao M, et al. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria [J]. Am J Physiol Renal Physiol, 2005,288:642-649.
14. Ozanne SE, Jensen CB, Tingey KJ, et al. Decreased protein levels of key insulin signalling molecules in adipose tissue from young men with a low birthweight-potential link to increased risk of diabetes [J]. Diabetologia, 2006,49:2993-2999.
15. Marcus G, Friedrich H. Inhibitor of glycogen synthase kinase (GSK) 3 promotes replication and survival of pancreatic beta cells [J]. J Biol Chem, 2007, 282: 12030-12037.
16. Gary WC, Kirk J, Werner R, et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats [J]. Diabetes, 2002,51:2903-2910.
17. Coghlan MP, Culbert AA, Cross DA. Selective small molecular inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and transcription [J]. Chem Biol, 2000,7;793-803.
18. Batya P, Oksana K. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3 [J]. J Pharmacol Exp Ther, 2003,305:974-980.
19. Rao R, Hao CM, Redha R, et al. Glycogen synthase kinase 3 inhibition improves insulin-stimulated glucose metabolism but not hypertension in high-fat-fed C57 BL/6J mice [J]. Diabetologia, 2007,50:452-460.
20. Murray JT, Campbell DG, Morrice N, et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3 [J]. Biochem J, 2004,384:477-488.
21. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes [J]. Liver Physiol, 2002,283: 204-211.
22. Yu JY, Taylor J, DeRuiter SL, et al. Enhancement of RNAi activity by improved siRNA duplexes [J]. Mol Ther, 2003,7:228-236.
23. Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle [J]. J Pharmacol Exp Ther, 2006,316:17-24.